All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
Illinois Vol.11 (corporations: AbbVie)
上記リンク内に無い本日までのツイート
“The beauty of science and medicine is that it is always growing and changing.” Learn what Margot Goodkin on our #ophthalmology clinical development team sees for patients with eye diseases: https://t.co/lfDrwJ1iiA #ScientistsRock pic.twitter.com/DwOiLeQJg6
— AbbVie (@abbvie) October 21, 2020
JUST IN: This morning we announced our @US_FDA and @EMA_News submission in #atopicdermatitis. Learn more: https://t.co/GqBWMkeKiV pic.twitter.com/sf9q9SnSC8
— AbbVie (@abbvie) October 19, 2020
The future of #rheumatology? With a greater understanding of the disease, more people with #RA could have a chance for remission. Read more: https://t.co/F05zmsv9XH pic.twitter.com/TNyEYVpVgg
— AbbVie (@abbvie) October 19, 2020
Read about our combination treatment, which has been granted full approval by the @US_FDA for newly-diagnosed acute myeloid leukemia patients who are ineligible for intensive chemotherapy due to age or comorbidities. https://t.co/E4kEza2Wd2 pic.twitter.com/tbmzfu5A4v
— AbbVie (@abbvie) October 17, 2020
Itchy skin, a symptom of atopic dermatitis – also known as eczema – can cause sleep disruption and lead to symptoms of depression and anxiety. Learn more about this chronic skin condition: https://t.co/zAGqUTbgzf#unhideECZEMA #EczemaAwarenessMonth pic.twitter.com/oD17x7CgQQ
— AbbVie US (@AbbVieUS) October 21, 2020
https://twitter.com/AbbVie_AU/status/1318303724301963264
#Google Spinoff #CalicoLifeSciences Enters its First Clinical Trial with #AbbVie Cancer Drug ABBV-CLS-S579 https://t.co/H7N9CjBX2J #clinicaltrials #cancerdrugs #healthcare #abbvclss579
— TrialSite News (@TrialsiteN) October 22, 2020
In September, $IMAB licensed rights for its anti-CD47 inhibitor to AbbVie. Brad Loncar writes about the deal and what he thinks this means for the CD47 space at large. https://t.co/X11lOh4FTG pic.twitter.com/Dy2Bb9seSh
— Loncar Biotech ETFs (@LoncarFunds) October 21, 2020
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis >>RFP@ bd@mellalta.com> #mellaltameethttps://t.co/HY4h36kXa0
— Mellalta Meets (@mellaltameets) October 21, 2020
AbbVie’s Allergan Aesthetics brand gets a facelift https://t.co/BzvtfloRcG
— cafepharma (@cafepharma) October 21, 2020
#AbbVie Announces Commencement of Registered Exchange Offers https://t.co/V22smFPl6b
— 1stOncology (@1stOncology) October 20, 2020
@abbvie has announced that the @US_FDA approved a new use of its B-cell lymphoma 2 inhibiting drug #Venclexta in the treatment of AML for some patients. https://t.co/QXcLTf8eoC pic.twitter.com/cwanJDKlsb
— LabPulse (@LabPulse1) October 20, 2020
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis | Small Molecules | News Channels – https://t.co/1KdcMjshu3 https://t.co/M9a8MbW3RL #drug #sting
— US Drug News (@USDrugNews) October 20, 2020
In today's News Briefing: AbbVie and Roche’s Venclexta got a new #FDA thumbs up. And ImmunoGen is picking up $40 million in cash from its new partner, Huadong Medicine.https://t.co/BMgst4quQ8
— Endpoints News (@endpts) October 20, 2020
AbbVie and Roche’s Venclexta (venetoclax) Receive the US FDA’s Approval for Acute Myeloid Leukemia https://t.co/RvvC9uD8wj
— PHARMABOX.in (@pharmabox_in) October 19, 2020
@us_FDA grants full approval to venetoclax @abbvie @genentech regimen for certain patients with newly diagnosed acute myeloid leukemia https://t.co/bGB0NCuYPf with comments from Lee Greenberger, PhD @LLSusa pic.twitter.com/WBiPEpuOjg
— HemOnc Today (@HemOncToday) October 19, 2020
The @US_FDA has fully approved @abbvie #Venclexta in acute myeloid leukaemia (AML).
For full article visit: https://t.co/Nf4Uce07io#cancernews #cancerdata #drugapproval— Larvol (@Larvol) October 19, 2020
Read: @abbvie pipeline drug tested as COVID-19 treatment (via @CrainsChicago) https://t.co/qSaGdyDneW
— IMA TODAY (@IMA_Today) October 19, 2020
AbbVie’s Venclexta granted full US approval in AML https://t.co/TGQ5rmtlM9 pic.twitter.com/W9n11lTKM3
— PharmaCrowd (@PharmaCrowd) October 19, 2020
Combination therapies involving @Roche and @AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage studies https://t.co/09bS6Cx1fY
— pharmaphorum (@pharmaphorum) October 19, 2020
https://twitter.com/hongkong_israel/status/1318093734387613696
.@abbvie submitted applications for U.S. and European approval of its immunology drug Rinvoq for the treatment of patients with moderate to severe atopic dermatitishttps://t.co/BZKlMihLhS $ABBV pic.twitter.com/GInCcSIIs0
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020
.@Roche @abbvie's Venclexta granted full US approval for blood cancer indication https://t.co/JPsTWRDfNb $ROG $ABBV pic.twitter.com/lbXANkZlBV
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020
Roche-AbbVie's #Venclexta granted full US approval for blood #cancer indication @Roche @abbvie https://t.co/KBOeUVtWyX pic.twitter.com/eHkLHSU1t2
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020
AbbVie, Molecular Partners to withdraw EU, Japan applications for #eye therapy @abbvie @MolecularPrtnrshttps://t.co/ynJSf1NVxe pic.twitter.com/Yo6GUuG5L7
— Market Intelligence: Healthcare (@SPGMIHealthcare) July 20, 2020
AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis @Pharmashot @abbvie https://t.co/ZTUHBymu3B pic.twitter.com/Mn7qfv2Guw
— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 20, 2020
AbbVie and Roche’s Venclexta (venetoclax) Receive the US FDA’s Approval for Acute Myeloid Leukemia @Pharmashot @abbvie @Roche https://t.co/sxljcSi8VT pic.twitter.com/9jZa59Z1oa
— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 19, 2020
.@AlexWestchester reports.@NIAIDNews clinical trial examines .@GileadSciences' remdesivir and antibody candidates by .@humanigen, .@Boehringer, and .@abbvie vs. #COVID19. Read more: https://t.co/DXhw6YJyKo pic.twitter.com/gP0SDRAG0n
— Genetic Engineering & Biotechnology News (@GENbio) October 17, 2020
"We are grateful to AbbVie for helping our city obtain the latest and best technology available to combat gun violence," North Chicago Mayor, Rockingham, Jr. said. "ShotSpotter is one more resource our police department will have to make our streets safer https://t.co/w9GRKNLqd4
— Ralph Clark (@ralphaclark) October 17, 2020
NIH initiates ACTIV trial for COVID-19 immune modulators @NIH @JanssenUS @bmsnews @abbvie https://t.co/YrxhDG2Ti4
— The Science Advisory Board (@ScienceBoard) October 16, 2020
"60% reduction in call volumes to service centers was achieved with the help of MyGuide Digital Adoption Platform" – Sandip Patel,@abbvie. Watch and learn how @MyGuideOrg enabled @abbvie to drive seamless employee software-onboarding experiencehttps://t.co/8Q8siHpI9S @karlmehta
— MyGuide by EdCast – Leader in Digital Adoption (@MyGuideOrg) October 16, 2020
The @uspirg contends @abbvie's patent thicket for Humira (adalimumab) will encourage anticompetitive practices by other manufacturers. $ABBV
Read more: https://t.co/MjnS4LjoQH pic.twitter.com/2qDs4AyMpM
— CenterForBiosimilars (@BiosimCenter) October 14, 2020
Amicus brief filed Monday against the maker of Humira. “As the records demonstrate,…@AbbVie engaged in a patent thicket strategy that allowed the company to prolong its Humira monopoly for years beyond what Congress intended.” #RxDrugs https://t.co/5GKzNe9fMz
— U.S. PIRG (@uspirg) October 14, 2020
Bond like $abbv https://t.co/P0bWzE9igu
— WhiteSands Trader (@contango15) October 22, 2020
https://t.co/NlQbz5M03t$TSCO $INTC $MMM @3M @intel $APO $ABBV @abbvie $BNS $SPG
— StocksDiscovery (@StocksDiscovery) October 21, 2020
AbbVie: Now It's Time To Dollar-Cost-Average On This 5.6% Yield (NYSE:ABBV) – https://t.co/NdKV5dWrWK pic.twitter.com/t7AiNomvQI
— Finanz (@FinanzDK) October 20, 2020
4 AbbVie brands land on pharma's top TV spenders list for September https://t.co/Vy1QJyfN6o pic.twitter.com/RUIc94HBsb
— analyst land news (@analystlandnews) October 16, 2020
Thank you to all who participated in @AbbVieUS SF Bay Area Virtual Partnering Day Plenary Session & Panel Discussion! We heard from AbbVie executives about their approach to partnerships and learned about their areas of interest across several therapeutic areas. pic.twitter.com/CPY22EMH3P
— California Life Sciences Association (CLSA) (@CALifeSciences) October 21, 2020
Explore this new technology! @4P_Pharma @abbvie @LillyPad @EvgenPharma @intlstemcell @Merck @Novartis @GSK @pfizer @PharmaLinkInc @TakedaPharma @zimmerbiomet @FlexionInc
— UF Innovate (@UFInnovate) October 20, 2020
Hosted by @CrohnsColitisFn and sponsored by @abbvie, Dr. Bohm and the IU Team will be participating in a virtual spooky #trivianight! We welcome you to participate to learn what will be happening in #IBD in 2020, as well as some costume contest fun! https://t.co/PaTe76iKlK pic.twitter.com/hCHFBbsaga
— Indiana University Gastroenterology (@IUGastro) October 20, 2020
NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr https://t.co/N6R2gcOqEZ
— Joey Sales (@sales_js) October 21, 2020
NIH to test J&J, AbbVie, Bristol Myers Squibb drugs as COVID-19 treatments
The National Institutes of Health plans to test three drugs from Johnson & Johnson, AbbVie and Bristol Myers Squibb as treatments for COVID-19, The Wall Street Journal reported. https://t.co/5ZMXzeCg7f pic.twitter.com/Dkk4bvloVH
— PharmacyWeek (Kevin) (@PharmacyWeek) October 21, 2020
NIH launches trial to uncover if #immunemodulatordrugs from Johnson & Johnson, Bristol Myers Squibb, and Abbvie can restore balance to overactive immune systems in #COVID-19 patients. https://t.co/x861DOUYLb
— pharmanewsintel (@pharmanewsintel) October 20, 2020
NIH to test J&J, AbbVie, Bristol Myers Squibb drugs as COVID-19 treatments https://t.co/7nkaab5BlS pic.twitter.com/5JZV3vRsZG
— Amber Deese Owens (@AmberOwens18) October 19, 2020
NIH launches COVID-19 test of J&J, Bristol Myers and AbbVie anti-inflammatory drugs | FiercePharma https://t.co/ry1qO7XT7r
— R Mandy Alcuria (@AlcuriaRudolph) October 19, 2020
AbbVie re-ups glaucoma awareness campaign with NFL star Miller https://t.co/oUTvAjxIrc
— NewExpressNews (@NewExpressNews) October 20, 2020
#WeekendReview California AG Joins Coalition Against AbbVie’s Alleged Anticompetitive Practiceshttps://t.co/3MSQWVTrwS
— CPI (@CompPolicyInt) October 18, 2020
CEO of CTYX posted another article on LinkedIn AbbVie to develop and sell China-based I-Mab's cancer drug | Article [AMP] | Reuters https://t.co/SDEsl1OGKs
— Eagle1xOne (@Eagle1xOne) October 21, 2020
Tony Au, general manager of AbbVie China, said, "We are excited about this opportunity and hope to show our commitment to making a remarkable impact on the lives of patients in China." The US firm will participate in the #CIIE for the first time. #WhatTheySay pic.twitter.com/Cd3EpiS5rY
— China International Import Expo (@ciieonline) October 19, 2020
https://twitter.com/fibroidsupport/status/1289126069841399808
Thx to: @abbvie, @accenture, @Aptiv, @Bordbia, @CancilleriaCol, @Entirl, @IDAIRELAND, @InnpulsaCol, @investinbogota, @IrelandiaAvi, @VivaAirCol, @kerryfoodgroup, @MRP_Latam, @Pernod_Ricard, @PlanetPayment, @RubiconCapAdv, @SEPAM_group, @SMBCAVIATION, @smurfitkappa, @PROCOLOMBIACO
— Embajada de Irlanda en Colombia y Panamá (@IrelandColombia) October 20, 2020
#15 position for #AbbVie in the #WorldsBestWorkplaces List by #GreatPlaceToWork!
Congrats! #BestCompany @abbvie @AbbVieItalia #BestCompany2020 #Gptw4all #gptw pic.twitter.com/54Rdw7nKtw— GPTW Italia (@GPTWItalia) October 14, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
A new treatment option in #hepC has just been approved in Japan. Learn more about our exciting news: https://t.co/froz8AgrmO pic.twitter.com/JtQEv0r2gT
— AbbVie (@abbvie) September 27, 2017
#DRG epidemiology report estimates more than 40 million people living with #atopicdermatitis across the United States, Western Europe and Japan @DRGinsights @abbvie #EADV #atopiceczema https://t.co/GzTMBYq1Ve
— DRG Epidemiology (@DRG_Epi) September 14, 2018
Japan awards AbbVie's Skyrizi with first approval, in 4 #psoriasis indications https://t.co/Kfvuazvhrf #pharma pic.twitter.com/safBoeH4EK
— Pharmafocus (@Pharmafocus) March 27, 2019
#Humira's approval in Japan shows that #AbbVie strives to increase its global market share while also increasing the number of indications it can treat with this #biologic. https://t.co/ZZuGEsNTrG
— GlobalData Pharma (@Pharma_GD) March 7, 2019
AbbVie Japan Alters Company Rules for Same-Sex, Common-Law Marriages The Japan arm of AbbVie has changed its company regulations to provide employees who are in same-sex… https://t.co/Xhi9Hp6fVk
— MEDWAVE (@medinfoa2z) August 17, 2020
De momento contento de llevar $ABBV
AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come $ABBV https://t.co/KRaIiZzu7T
— Josue (@goldesenyo) April 12, 2019
Another great option for people with #psoriasis. #AbbVie gets the first global regulatory approval of #SKYRIZI in Japan https://t.co/Jn6OgT2EbF via @AsiaBioSpectrum
— International Psoriasis Council (@IpcPs) March 27, 2019
$ABBV – AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come https://t.co/6bTcWFL6WE
— Jeffrey Weber (@jjjinvesting) April 11, 2019
Hats off to all the American companies that are pitching in to help Japan recover from Typhoon Hagibis. Among them are @united, @Merck, @abbvie, and @KEEN. Oregon Governor Brown and I met with representatives of @KEEN_Japan to extend our appreciation. pic.twitter.com/v2ieUTdmvC
— ジョセフ・M・ヤング 駐日米国臨時代理大使 (@USAmbJapan) November 21, 2019
Galapagos: Chasing AbbVie, Gilead files for approval of filgotinib in Japan $GLPGhttps://t.co/4xtyxlLMWR
— Lama Daila (@Lama_Daila) October 8, 2019
#AbbVie receives priority review for new 8-week DAA in Japan https://t.co/R3Lmmj3zG8 #HCV
— Healio Hepatology (@HealioHep) March 15, 2017
AbbVie's Viekirax approved as #HCV treatment in Japan: http://t.co/LwtqdFmT8s @AbbVie RT pic.twitter.com/KPV1ifdAwh
— European Pharmaceutical Review (@PharmaReview) October 1, 2015
With hep C approval app, AbbVie eyes franchise growth in Japan http://t.co/doMYaxyJlM $ABBV #pharma via @FiercePharmAsia
— FiercePharma (@FiercePharma) February 12, 2015
https://twitter.com/galamericas/status/1317122908829908992
AbbVie, Amgen and Takeda team up for joint COVID-19 trial – PMLiVE https://t.co/l47HbqyU9v
— Pharmaceutical Market Europe (@PMLiVEcom) August 5, 2020
AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study https://t.co/IzrYEnmjmV
— PhRMA (@PhRMA) August 4, 2020
AbbVie, Amgen and Takeda jointly study impact of anti-inflammatory drugs in COVID-19 treatment @ExpPharma https://t.co/jWG55UmxUE
— IJPSonline (@IndianJPharmSci) August 4, 2020
AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study https://t.co/1IlYuJzeVe
— iBIO (@IllinoisBiotech) August 4, 2020
Rival drugmakers launch joint trial of drugs for #COVID19 https://t.co/LcRNln9jaK @gulf_news #coronavirus @AbbVie @Amgen @Takeda
— Gulf News Business (@GulfNewsBiz) August 3, 2020
AbbVie, Amgen, Takeda launch joint trial of potential COVID-19 drugs https://t.co/J2kmg2aHtE
— FirstWord Pharma (@fwpharma) August 3, 2020
Abbvie, Amgen and Takeda begin patient trial for Coronavirus vaccine https://t.co/j43q68CeRs
— PageOne.ng (@PageOne_NG) August 3, 2020
AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments https://t.co/d8RdZY3U1g
— MarketsTicker (@MarketsTicker) August 3, 2020
AbbVie, Amgen and Takeda begin testing drugs as COVID-19 treatments https://t.co/3V3KhrwqAT
— MarketWatch (@MarketWatch) August 3, 2020
Rival drugmakers AbbVie Inc , Amgen Inc and Takeda Pharmaceuticals Inc. said they have begun treating patients in a trial. | @reuters https://t.co/5EJHUF7fmQ
— Inquirer (@inquirerdotnet) August 3, 2020
#covid19 cases seem to be reducing in Italy & China. Plus masses of big biotech, pharma & vaccine companies are pouring $bns into finding a cure, eg Gilead, Pfizer, GSK, Takeda, AbbVie, Moderna.
I appreciate no-one has the answer yet, but I suspect they'll get before the y/e pic.twitter.com/haEYH2cUOZ
— PMH Capital (@CapitalPmh) March 4, 2020
Takeda's Entyvio outperforms AbbVie's Humira in moderate-to-severe #UlcerativeColitis https://t.co/RBvxGE4VEN #pharma pic.twitter.com/8duoTU0NH1
— Pharmafocus (@Pharmafocus) September 27, 2019
pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in: Novartis, Merck, GlaxoSmithKline (GSK), Gilead, Bayer, AstraZeneca, AbbVie and Takeda offered their opinions on recent FDA draft guidance on potential drug-drug interactions… https://t.co/usSBncXDwt
— cafepharma (@cafepharma) July 27, 2018
Great opportunities for @ucdscience and engineering students/grads:
☑️NIBRT Careers in Biopharma event in UCD Campus on 13 April
☑️Companies attending include J&J, BMS, Sanofi, Allergan, Amgen, Grifols, Takeda, AbbVie
☑️Further details on https://t.co/zpHbKRFHvq. https://t.co/0N3eoSrKZK
— UCD Chemistry (@ucdchemistry) March 20, 2019
On Saturday, IPhO held its 4th annual Pharma Fair! Student pharmacists from over the country came to network with reps from pharmaceutical companies such as Takeda, AbbVie, & more.
Our students are making key connections that will put them on the path to success! pic.twitter.com/6sGk11Cz4e
— UIC Pharmacy (@UICPharm) October 28, 2019
Takeda buy Shire
BMS buy CellgeneAnd now … Abbvie buy Allergan
All are BIG players with significant stakes in current / future therapies for #IBD
It will be very interesting to watch this play out. Hopefully it means more R&D investment that translates to the clinic. pic.twitter.com/EpoUnt9yXD
— Charlie Lees (@charlie_lees) June 25, 2019
MSBE, BT and GCB students check out the Careers in Biopharma event in NIBRT on April 13th 2019. Companies attending include J&J, BMS, Sanofi, Allergan, Amgen, Grifols, Takeda, AbbVie.
Further details on https://t.co/pqVYveVS0o
— Brian Freeland (@BFreelandDCU) March 19, 2019
Big Pharma’s first female CEO is engineering a radical shake-up, taking a different path than Bristol-Myers Squibb, Takeda Pharmaceutical, and AbbVie, which are reinventing themselves with megadeals.
Read more at: https://t.co/kirykEPAe0
— menaka doshi (@menakadoshi) July 18, 2019
8 New drug structures revealed at #ACSOrlando….see them here !
Companies include: Amgen, Abbvie, Novartis, Takeda, Pfizerhttps://t.co/ZE68xbb5r7 pic.twitter.com/tYbPMJ45Gj— Organic Process Research & Development (@OPRD_ACS) April 5, 2019
Endometriosis Treatment Market New Opportunities For Growth And Profitable Business Development 2026 Evaluated By Global Players Meditrina Pharmaceuticals, Abbvie, PfizerInc, Takeda Pharmaceutica, and Neurocrine Biosciences Inc https://t.co/HhbepHFlxV via @openPR
— Raj Bisen (@Rajbisen210) February 26, 2019
https://twitter.com/AxiomaGroupInc/status/1301584540507439109
J&J may be a little behind with the COVID-19 vaccine, but they may still have an advantage.https://t.co/T4ubxOcCdg#competitiveadvantage #vaccine #strategy #jnj #pfizer #allergan #takeda #abbvie #amgen #moderna #covid19 #pharma #biopharmaceuticals #biopharma #coranavirus #lead pic.twitter.com/OiE3GZXTcX
— Axioma Group, Inc. // Strategy + Innovation (@AxiomaGroupInc) August 12, 2020
https://twitter.com/AxiomaGroupInc/status/1291191015701872643
Prostate Cancer Diagnosis and Treatment Market Supply-Demand, Industry Research and End User Analysis, Outlook 2026 | COVID19 Impact Analysis | Key Players: Abbott Laboratories, AbbVie, Active Biotech, Amgen, Astellas Pharma, etc. https://t.co/SReC9xp1Jy
— mednetnews (@mednetnews) October 2, 2020
https://twitter.com/KNOW_AML/status/1252583034622263297
Cancer Therapeutics Market Estimated to Reach at $178,863 million by 2023 – F. Hoffmann-La Roche,Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Celgene, Astellas, Pfizer, Novartis, Merck, Eli Lilly – Downey Magazine https://t.co/0lBoYnbg4h
— Cross the Creek (@creek_cross) December 26, 2019
Research Segment of Endometriosis Drugs Market (2020 – 2029) | AbbVie, Astellas Pharma, AstraZenecahttps://t.co/Zz5keb7j2s#news #pharma #pharmiweb
— Pharma News (@pharminews) December 23, 2019
Global Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Evolving Opportunities with AbbVie Inc. and Astellas Pharma Inc. | Technavio https://t.co/MScX9lj3gm
— Pharmacutical Daily (@PharmacDaily) November 5, 2019
Don't be left out of the celebrations – Entries from @abbvie @Bayer @astellas @Novartis @JanssenUS already, so don't miss out on your chance to be part of the #efpawards Download your entry pack here https://t.co/Trk5qhLrNR pic.twitter.com/3ibsDJAd67
— Reuters Events Pharma (@RE_Pharma) June 25, 2019
Biopharmaceuticals Market Outlook to 2025 :Inflammatory , Infectious Diseases, Autoimmune Disorders, Metabolic Disorders,| With Top Key Players AbbVie, Amgen Astellas BioPharma, Johnson & Johnson, No https://t.co/EexNJ7Z3l2
— PressRelease.cc (@PressRelease_cc) February 19, 2019
Global Prostate Cancer Drugs Market 2018 Top Intelligence:- AbbVie, Astellas Pharma, Astra Zeneca, Johnson & Johnson, Sanofi https://t.co/OaKEt1Qsin
— Tammy V Wyatt (@tammyvwyatt) January 21, 2019
Hear from Abbvie, Novant Haelth, Astellas, and more at the Strategic Internal Comms for Health Care in April – https://t.co/NUsASWbuVz
— ALI Conferences (@aliconferences) March 16, 2017
NIH launches COVID-19 test of J&J, Bristol Myers and AbbVie anti-inflammatory drugs https://t.co/mmnoWBwa4Y #NIH #JohnsonAndJohnson #BristolMyersSquibb #AbbVie #AntiInflammatoryDrugs https://t.co/vE5QbcsRYJ
— Haybury (@Hayburysearch) October 20, 2020
Bipolar disorder therapeutics market: Top players are Novartis AG, Allergan, Otsuka Holdings, AbbVie etc. – Credence Turbine https://t.co/r9Q5pnDX42
— Schizocidal (@schizocidal) July 10, 2020
Autism Disorder and Treatment Market Growth 2026: Including Key Players Otsuka, AstraZeneca, Pfizer, AbbVie, Johnson & Johnson Services, GlaxoSmithKline https://t.co/8GAlL0MDgR
— Market Research Nest (@marketrnest) April 6, 2020
The $200 discount for the Marketing Disruption Summit ends Friday! Explore the full agenda and get your tickets here: https://t.co/sueo5mBZEd#sanofi #BMS #ferring #boehringeringelheim #merck #teva #gsk #abbvie #astrazeneca #pfizer #bayer #otsuka #us #pharma #marketing #data #it pic.twitter.com/u9P8j4mLcn
— Reuters Events Pharma (@RE_Pharma) August 14, 2019
Japan Oncology Drugs Market Opportunities with Leading Players: Daiichi Sankyo Co Ltd, AstraZeneca plc, AbbVie Inc., Celgene Corporation https://t.co/cTWBLWxisp
— Aditi Desai (@Aditi04986849) November 28, 2019
New post (Humira Market Report Expected Massive Growth By 2020-2025 | AbbVie, Eisai, Torrent Pharmaceuticals) has been published on https://t.co/fdzRB6KRVD – https://t.co/ioErwtJuF5 pic.twitter.com/enQI4mWqu9
— Top News Corner (@topnewscorner) September 15, 2020
Humira Market (2020-2029) : Ranking down the Industry System, Geography and Business sections of the major players AbbVie, Eisai, Cadila Healthcarehttps://t.co/2fA5xvIEqd#news #pharma #pharmiweb
— Pharma News (@pharminews) January 28, 2020
Strategic Overview of the Global Humira Market Exploring the Present and Future State -AbbVie, Eisai And Cadila Healthcare – https://t.co/QnvrzJt4eF #pharma #news
— Pharma News (@pharminews) July 15, 2019
AbbVie and Eisai Announce Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa | News Release：2019 | Eisai Co., Ltd. https://t.co/HE4j8WWYlh
— Krishan Maggon (@kkmaggon) February 22, 2019
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA https://t.co/2jOFyHj7qY pic.twitter.com/ZmYb9G36JO
— Haleplushearty.org (@haleplushearty) February 21, 2019
AbbVie and Eisai obtain additional approval for Humira https://t.co/hQFi3njXEo via @NewsNowUK
— francis loos (@claoseun) April 3, 2018
